Galván-Manso M, Campistol J, Monros E, Póo P, Vernet A M, Pineda M, Sans A, Colomer J, Conill J J, Sanmartí F X
Servicio de Neurología, Unidad Integrada, Hospital Sant Joan de Déu-Hospital Clínic. Universidad de Barcelona, Barcelona, España.
Rev Neurol. 2002;35(5):425-9.
Angelman syndrome (AS) is characterised by mental retardation, ataxic gait, epilepsy, absence of language and a special series of physical traits behavioural phenotype. Its incidence is estimated as one in every 20,000 individuals. On the basis of discoveries made in molecular biology, patients can be classified as belonging to five types: deletion, paternal uniparental disomy (UPD), imprinting defects, mutation of the UBE3A ubiquitin protein ligase gene and unidentified mechanism (15% 20% of patients). Some studies report significant correlations between the phenotype and the genetic cause.
We reviewed, retrospectively, 37 patients suffering from AS with a positive genetic study and who had been controlled for at least two years in the Neurological Service at the Hospital Sant Joan de D u. Data was collected on physical characteristics, behavioural phenotype, type of communication, sleep disorders and the medication they needed, as well as epilepsy, start age, types of seizures, medication, schooling and social integration.
87% of cases were due to de novo deletion, 8% were caused by UPD, and 5% had their origins in imprinting defects. The average age of diagnosis was 6.5 years. The sleep disorders present in 48% of the patients required medication in 67% of cases, and 95% presented epilepsy. The most frequent seizures were myoclonic, tonic clonic and atonic. The electroencephalogram (EEG) was the characteristic found in the AS in 68%. The most effective treatment was afforded by valproate and clonazepam.
As regards the phenotype, no differences were found according to the genetic alteration. The most effective treatment for the sleep disorders was melatonin. Epilepsy was an almost constant finding in our series, as was cognitive affectation. Lastly, it must be pointed out that educational and socio occupational integration is difficult for patients suffering from AS.
天使综合征(AS)的特征为智力迟钝、共济失调步态、癫痫、无语言能力以及一系列特殊的身体特征和行为表型。其发病率估计为每20000人中1例。基于分子生物学的发现,患者可分为五种类型:缺失型、父源单亲二倍体(UPD)、印记缺陷型、泛素蛋白连接酶E3A(UBE3A)基因突变型以及不明机制型(占患者的15% - 20%)。一些研究报告了表型与遗传病因之间的显著相关性。
我们回顾性研究了37例经基因检测确诊为AS且在圣琼·德乌医院神经科至少接受了两年治疗的患者。收集了他们的身体特征、行为表型、沟通方式、睡眠障碍及所需药物,以及癫痫情况、发病年龄、癫痫发作类型、用药、受教育程度和社会融入情况等数据。
87%的病例为新发缺失型,8%由UPD引起,5%源于印记缺陷。平均诊断年龄为6.5岁。48%的患者存在睡眠障碍,其中67%需要药物治疗,95%的患者患有癫痫。最常见的癫痫发作类型为肌阵挛性、强直阵挛性和失张力性发作。68%的AS患者脑电图(EEG)有特征性表现。最有效的治疗药物是丙戊酸盐和氯硝西泮。
就表型而言,未发现因基因改变而存在差异。治疗睡眠障碍最有效的药物是褪黑素。在我们的研究系列中,癫痫几乎是一个恒定的表现,认知功能障碍也是如此。最后,必须指出的是,AS患者在教育和社会职业融入方面存在困难。